Ginkgo Bioworks Holdings, Inc.

Сильный индекс, значительно вырос. Быки крепко уверены в своих позициях.

Strong index, significantly up. The bulls are very confident in their positions.

Сильный индекс, без изменений. Рынок на стороне быков.

Strong index, flat. The market is on the bulls' side.

Сильный индекс, значительно упал. Отток средств из лонгов увеличился и находится на высоком уровне.

Strong index, significantly down. The outflow of funds from longs has increased and is at a high level.

(RTTNews) - Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.
Major highlights include FDA approvals for Ultragenyx's FAYUVI, Bayer's Kerendia, and Telix's Pixclara, while Biogen and Eisai expanded LEQEMBI's reach in Japan with a new at-home administration option. Elsewhere, Sionna announced significant workforce reductions, and deal activity remained strong, with transactions involving Roche, GSK, Novo Nordisk and Anthropic.
Clinical developments also remained in focus, with positive updates from Roche's Lunsumio, Akeso's Ivonescimab, AstraZeneca's TAGRISSO and Vera Therapeutics' TRUTAKNA, while studies from Longeveron and Contineum fell short of key efficacy goals.
Here's a roundup of the week's notable biotech developments...
FDA Approvals
Ultragenyx Pharmaceutical Inc. (RARE) secured U.S. FDA approval for FAYUVI (rebisufligene etisparvovec), the first approved treatment for Sanfilippo syndrome Type A, a rare and fatal neurodegenerative disorder. The approval was supported by data demonstrating rapid and sustained reductions in cerebrospinal fluid heparan sulfate, a key disease biomarker, as well as long-term clinical outcomes from treated patients. FAYUVI will be available through a network of Qualified Treatment Centres.
RARE closed Thursday's trading (September 17, 2026) at $14.50, up 12.58%
Nuvation Bio Inc. (NUVB) received FDA approval for a sNDA label update for IBTROZI (taletrectinib) in adults with advanced ROS1 positive NSCLC. The revised label includes long term data from the TRUST-I and TRUST-II studies showing a median duration of response of 49.7 months in treatment- naïve patients, the longest reported for an FDA-approved ROS1 inhibitor.
IBTROZI is already approved for advanced ROS1+NSCLC, and the updated label adds extended efficacy data with no new safety signals identified.
NUVB closed Thursday's trading at $6.07, up 5.02%
Bayer AG (BAYRY) received FDA approval for Kerendia (finerenone) to treat adults with chronic kidney disease (CKD) associated with type 1 diabetes, becoming the first new treatment for this condition in more than 30 years. The approval was supported by Phase III FINE-ONE trial data, along with evidence from the Phase III FIDELIO-DKD and FIGARO-DKD studies. Kerendia is already approved in CKD associated with type 2 diabetes and for reducing heart failure-related risks in adults with preserved ejection fraction.
BAYRY closed Thursday's trading at $14.13, up 0.57%
Biogen Inc. (BIIB) and Eisai Co., Ltd. (ESALY.PK) received approval in Japan for LEQEMBI Pen, a subcutaneous autoinjector formulation of LEQEMBI (lecanemab) for patients with early Alzheimer's disease, including mild cognitive impairment and mild Alzheimer's dementia. The approval was based on data from the Phase III Clarity AD study and the subcutaneous formulation development program. LEQEMBI was previously available as an intravenous infusion every two weeks, and the latest approval adds a once-weekly at-home subcutaneous administration option for patients.
BIIB closed Thursday's trading at $219.05, up 1.41%
Beta Bionics, Inc. (BBNX) received FDA clearance for Mint, a new patch for insulin delivery in people with diabetes. The device features a reusable- disposable design, smartphone control, compatibility with Dexcom and Abbott CGM systems, and up to three days of wear time. In addition, the company sought FDA clearance for iLet 3D, its next-generation 3D Intelligence automated insulin dosing algorithm, with the launch expected to launch by year-end pending clearance.
BBNX closed Thursday's trading at $21.43, down 3.38%
Telix Pharmaceuticals Limited (TLX) received FDA approval for Pixclara (18F-FET), a PET imaging agent to differentiate recurrent or progressive glioma from treatment-related changes in adults and pediatric patients aged one month and older. The approval was supported by safety data from 382 glioma patients and establishes Pixclara as the first FDA-approved FET-PET imaging drug for glioma in the U.S. Telix is also evaluating Pixclara in a Phase III registrational study for a potential label expansion in brain metastases.
TLX closed Thursday's trading at $12.51, up 5.71%
Scholar Rock (SRRK) received FDA approval for ISEMBYLD (apitegromab-mstn) for adults and children aged 2 years and older with spinal muscular atrophy (SMA), who are receiving SMN2-targeted therapy. The approval was based on the Phase III SAPPHIRE study, where ISEMBYLD demonstrated clinically meaningful improvements in motor function after one year of treatment compared with SMN2-targeted therapy alone. ISEMBYLD is the first and only muscle-targeted therapy approved for SMA, addressing muscle function decline that persists despite existing SMN-targeted treatments.
SRRK closed Thursday's trading at $49.02, down 0.71%
Bausch + Lomb Corporation (BLCO) received CE Mark approval in the European Union for SeeLyra, its next- generation femtosecond laser platform for laser-assisted cataract surgery, LASIK flap creation and corneal therapeutic procedures. The approval covers a system featuring real-time swept source OCT imaging for enhanced surgical precision and workflow efficiency. Building on the company's VICTUS platform, SeeLyra will begin a limited European launch in the coming months, with broader availability expected in 2027.
BLCO closed Thursday's trading at $16.77, down 1.76%.
Layoffs
Sionna Therapeutics Inc. (SION) announced a workforce reduction of approximately 46% and other cost-cutting measures after deciding not to advance SION-719 following disappointing Phase 2a PreciSION CF results. The company will instead focus resources on advancing its SION-451 + SION-2222 dual combination into the AscenSION CF Phase 2a trial, scheduled to begin in the first quarter of 2027. Sionna expects the restructuring and discontinuation of SION-719 investment to extend its cash runway into the second half of 2029.
SION closed Thursday's trading at $7.18, up 1.99%.
Deals
Dualitas Therapeutics, Inc. announced a research collaboration and license agreement with Roche Holding AG (RHHBY) to advance bispecific antibodies for immunology and inflammatory diseases leveraging Dualitas' DualScreen Bispecific Discovery Engine.
Under the terms of the agreement, Dualitas will receive a $36.5 million upfront payment and may receive additional research, development and commercial milestones, bringing the total potential deal value to up to $1 billion, plus tiered royalties. Roche will be responsible for all subsequent preclinical development, regulatory, manufacturing and commercial activities.
RHHBY closed Thursday's trade at $54.63, down 0.94%.
Aethlon Medical, Inc. (AEMD) announced a merger agreement with privately held North Immunology to advance development of NOR-101, an IL-13 x IL-18 bispecific antibody for atopic dermatitis, alongside an oversubscribed $180 million private placement.
Under the proposed transaction, existing Aethlon stockholders are expected to own approximately 4.75% of the combined company at closing, while existing North Immunology stockholders, including investors participating in the financing, are expected to own approximately 95.25%.
The combined company is expected to have a pro forma equity value of approximately $346.5 million, including the private placement, and the merger is expected to close in the first quarter of 2027.
The combined company will operate as North Immunology, Inc., trade on Nasdaq under the ticker NRTX, and expects its oversubscribed $180 million private placement to fund operations into the second half of 2028.
AEMD closed Thursday's trade at $6.78, up 373.13%.
Novo Nordisk A/S (NVO) and Anthropic, the Claude AI platform developer, announced a collaboration to help Novo accelerate the development of new medicines and advance AI-driven software development.
Novo will use Anthropic models and Claude Science to advance scientific reasoning for Research and Development (R&D) and agentic software engineering. As an initial step, Novo will test Claude Science in selected research areas and address scientific problems where the joint capabilities of Novo and Anthropic are viewed to have a great impact.
NVO closed Thursday's trading at $43.19, up 3.55%
Ginkgo Bioworks Holdings, Inc. (DNA) announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, an AI/ML drug discovery platform created by Eli Lilly and Company. (LLY).
Ginkgo Datapoints offers biological data generation services, and TuneLab gives participating biotech companies access to AI/ML models trained using decades of Lilly research data.
Ginkgo Datapoints will provide discovery data generation services, including small molecule developability (ADME) and antibody developability testing, to TuneLab companies. Ginkgo's standardised assay protocols across the TuneLab ecosystem are expected to help AI/ML models learn more efficiently and enhance the platform's overall impact.
DNA closed Thursday's trade at $7.84, up 11.05%.
LLY closed Thursday's trading at $1152.44, up 1.28%.
Milestone Scientific Inc. (MLSS) announced that Dr. Sudhir Rao, Medical Director of Pain and Spine Specialists, an interventional pain management organisation, has joined Milestone Scientific as a development partner and member of the company's CompuFlo Advisor Program.
Through the program, Sudhir Rao and his team will provide guidance on clinical workflows, product enhancements, physician and staff experience, training initiatives, future applications, and product development efforts.
The collaboration will also provide Milestone Scientific with direct feedback from physicians and clinical teams performing interventional pain procedures.
MLSS closed Thursday's trade at $0.42, up 6.08%.
DataMEDS AI Inc. (MEDS) has acquired the Helomics AI cancer diagnostics laboratory and precision oncology contract research organization businesses from Axe Compute (AGPU), for a total purchase value of $1.5 million.
The transaction provides DataMEDS with Helomics' CLIA/CAP-certified clinical laboratory, all associated equipment, the Predictive Oncology CRO central lab services business and $1.5 million in cash, with no third-party debt attached to the acquired assets.
Under DataMEDS' ownership, Helomics is expected to expand beyond tumour molecular profiling and chemosensitivity testing into cancer screening, CLIA laboratory services, and nutritional support for cancer patients.
MEDS closed Thursday's trade at $4.64, down 23.56%.
British drug major GSK plc (GSK, GSK.L) announced that it has entered an agreement to acquire a potential best-in-class trispecific T-cell engager for multiple myeloma from privately held clinical-stage biotechnology firm Chimagen Biosciences for a total potential value of up to $750 million.
Under the agreement, GSK will pay an upfront fee for full global rights to the TCE program, with Chimagen eligible for development and commercial milestone payments.GSK expects to enter Phase I trials in 2027.
GSK closed Thursday's trade at $51.06, up 1.53%.
Clinical Trials - Breakthroughs & Setbacks
Roche Holdings AG (RHHBY) announced that the Phase 3 CELESTIMO trial evaluating Lunsumio (mosunetuzumab-axgb) in combination with lenalidomide versus Rituxan (rituximab) plus lenalidomide met its primary endpoint in the interim analysis in patients with relapsed or refractory follicular lymphoma (R/R FL) who had received at least one prior line of treatment.
According to the company, the combination demonstrated a statistically significant and clinically meaningful reduction in the risk of disease progression at the interim analysis.
RHHBY closed Thursday's trade at $54.63, down 0.94%.
Longeveron Inc. (LGVN) reported that the phase 2b ELPIS II trial evaluating laromestrocel, an investigational allogeneic mesenchymal stem cell (MSC) therapy, failed to meet its primary endpoint of improving right ventricular ejection fraction at 12 months in infants with hypoplastic left heart syndrome (HLHS).
The company said it would conduct additional analyses of the full dataset and plans to discuss the findings with the U.S. FDA to determine potential next steps for the HLHS program.
LGVN closed Thursday's trade at $2.71, down 59.43%.
Lunai Bioworks, Inc. (LNAI) announced a BioSymetrics study evaluating structure-based screening for generative AI-related chemical risks. The study assessed whether acetylcholinesterase (AChE) inhibition could be predicted directly from molecular structure as a model-agnostic component of Lunai's broader chemical-safety and biosecurity strategy.
Using NIH Tox21 data from 9,667 compounds, the model achieved an area under the receiver operating characteristic curve (AUROC) of 0.88. The model achieved 33% precision at 70% recall, a 5.1-fold enrichment over the 6.4% baseline prevalence.
The company cautioned that the study does not establish clinical neurotoxicity or real-world chemical hazards and requires further validation.
LNAI closed Thursday's trade at $2.27, up 4.84%.
Akeso, Inc. (AKESF, 9926.HK) announced positive overall survival (OS) results from the Phase III HARMONi-2 study of ivonescimab, an investigational immuno-oncology therapy, versus pembrolizumab as first-line treatment for patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
According to the company, Ivonescimab reduced the risk of death by 27% compared to Pembrolizumab and improved median overall survival by 8.2 months, with a manageable safety profile consistent with previous studies.
9926.HK closed Friday's trade at HK$90.50, down 0.28%.
Vera Therapeutics, Inc. (VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented disease progression in adults with primary IgA nephropathy (IgAN) over two years.
In the ORIGIN 3 study, TRUTAKNA slowed kidney function decline, with an annualised eGFR slope of -0.6 versus -5.6 for placebo, and reduced progression events by 76%.
TRUTAKNA currently has accelerated FDA approval for IgAN, and Vera plans to submit a supplemental Biologics License Application or sBLA in the fourth quarter of 2026, using the ORIGIN 3 confirmatory data to seek full approval.
VERA closed Thursday's trade at $34.27, up 7.87%.
Connect Biopharma Holdings Ltd. (CNTB) announced positive preliminary topline data from its global Phase 2 Seabreeze STAT Asthma study evaluating rademikibart, a fully human monoclonal antibody, as an add-on treatment for acute exacerbations in adults and adolescents with asthma and type 2 inflammation.
According to the company, Rademikibart significantly improved lung function at Day 7 and reduced asthma-related emergency or unscheduled visits by 50% versus placebo. However, the study's primary endpoint, treatment failure at Day 28, did not reach statistical significance despite a numerical reduction of about 66%.
CNTB closed Thursday's trade at $1.29, up 4.03%.
Contineum Therapeutics, Inc. (CTNM), a clinical-stage biopharmaceutical company, announced that the phase 2 MOONLIGHT-1 trial evaluating JNJ-5120/PIPE-307, an investigational selective inhibitor of the M1 receptor as monotherapy in adult participants with Major Depressive Disorder (MDD) did not achieve its primary efficacy endpoint.
The trial evaluated the improvement in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at day 5 from baseline compared with placebo. While the primary endpoint was not met, the company said JNJ-5120/PIPE-307 was well tolerated with no new safety signals.
Johnson & Johnson, which is developing JNJ-5120/PIPE-307, will further evaluate the data, including prespecified exploratory endpoints, to determine next steps.
CTNM closed Thursday's trade at $13.21, down 4.00%.
AstraZeneca PLC (AZN) updated exploratory results from the ADAURA Phase III trial show that TAGRISSO (osimertinib) delivered an eight-year landmark overall survival benefit in early-stage EGFR-mutated non-small cell lung cancer (NSCLC), marking the longest survival ever reported in a global Phase III trial in this setting.
AstraZeneca (AZN) reported updated exploratory results from the Phase III ADAURA trial showing that TAGRISSO (osimertinib) maintained an overall survival benefit at eight years in early-stage EGFR-mutated NSCLC.
According to the company, TAGRISSO showed a sustained overall survival benefit versus placebo, reducing the risk of death by 47% in patients with Stage II-IIIA disease and by 48% in the overall Stage IB-IIIA population. At eight years, survival was 74% versus 58% and 79% versus 64%, respectively, compared with placebo.
The findings represent the longest survival data reported from a global Phase III trial in this setting, the company said.
AZN closed Thursday's trade at $166.14, up 2.00%.
For more biotechstock news visit rttnews.com.

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

(RTTNews) - Ginkgo Bioworks (DNA) announced that its Ginkgo Datapoints offering has entered into a new agreement with Lilly TuneLab, an AI/ML drug discovery platform created by Eli Lilly and Company.
Under the agreement, Ginkgo Datapoints will provide discovery data generation services, including small molecule developability testing and antibody developability testing, to biotech companies participating in TuneLab.
The collaboration is designed to connect AI-generated drug discovery hypotheses with experimental laboratory data, allowing TuneLab participants to generate standardized, machine-learning-ready datasets for use with predictive models.
Ginkgo's automated laboratories are expected to enable TuneLab companies to conduct experiments without manual laboratory bottlenecks, with results generated in formats that can be integrated directly into TuneLab's predictive models.
The small molecule and antibody developability services are designed to provide experimental results in days rather than months, helping biotech companies evaluate AI-generated candidates through laboratory testing.
Ginkgo will also provide standardized assay protocols across the TuneLab ecosystem, which the companies expect will help AI/ML models learn more efficiently through additional experimental data.
New TuneLab members will be able to submit data generated through Ginkgo Datapoints to access additional platform model benefits.
The agreement expands Ginkgo Datapoints' work in providing biological data generation services for AI/ML-driven drug discovery and connects predictive models with real-world experimental data at scale.
Lilly TuneLab is part of Lilly Catalyze360, which also includes Lilly Ventures, Lilly Gateway Labs and Lilly ExploR&D.
The initiative supports biotech innovation through access to capital, laboratory space, technology and research and development capabilities.
Ginkgo Bioworks develops tools and autonomous laboratory systems designed to automate biological research and improve laboratory productivity.
Its Datapoints and Solutions businesses provide contract research and biological data generation services through its autonomous laboratory infrastructure.
Ginkgo Bioworks' shares are currently trading at $7.18, up 2.86%.

Ginkgo Datapoints Partners With Lilly TuneLab To Link AI Models And Lab Data

Palantir (NASDAQ: PLTR) and Ginkgo Bioworks (NYSE: DNA) sit on opposite sides of a fast-emerging biosecurity debate. Palantir represents the intelligence layer, while Ginkgo represents the biological infrastructure layer. The question is whether future value comes from identifying threats first or building faster biological responses.
Stock prices used were the market prices of June 18, 2026. The video was published on June 27, 2026.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Should you buy stock in Palantir Technologies right now?
Before you buy stock in Palantir Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $398,052!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,181,688!*
Now, it’s worth noting Stock Advisor’s total average return is 892% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of June 28, 2026.
Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think

(RTTNews) - Ginkgo Bioworks Holdings, Inc. (DNA) on Thursday reported third-quarter net loss of $80.76 million or $1.45 per share, compared to $56.40 million or $1.08 per share in the comparable prior year period.
Third-quarter total revenue was $38.84 million compared to $89.05 million in the comparable prior year period, a decrease of 56%.
Looking forward, Ginkgo reaffirms total revenue of $167 million to $187 million in 2025.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ginkgo Bioworks Holdings Q3 Loss Widens

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -25.52%. A quarter ago, it was expected that this company would post a loss of $2.40 per share when it actually produced a loss of $1.08, delivering a surprise of 55%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Ginkgo Bioworks, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $43.85 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 2.74%. This compares to year-ago revenues of $34.76 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Ginkgo Bioworks shares have added about 6.5% since the beginning of the year versus the S&P 500's gain of 1.7%.
What's Next for Ginkgo Bioworks?
While Ginkgo Bioworks has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Ginkgo Bioworks: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.23 on $45.16 million in revenues for the coming quarter and -$5.99 on $202.68 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
CytomX Therapeutics (CTMX), another stock in the same industry, has yet to report results for the quarter ended December 2024.
This biopharmaceutical company is expected to post quarterly loss of $0.20 per share in its upcoming report, which represents a year-over-year change of -2100%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
CytomX Therapeutics' revenues are expected to be $20.13 million, down 24.4% from the year-ago quarter.
Should You Invest in Ginkgo Bioworks Holdings, Inc. (DNA)?
Before you invest in Ginkgo Bioworks Holdings, Inc. (DNA), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ginkgo Bioworks Holdings, Inc. (DNA) : Free Stock Analysis Report
CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates

Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.

Ginkgo Bioworks Holdings To Present At J.P. Morgan Healthcare Conference; Webcast At 1:30 PM ET

(RTTNews) - Ginkgo Bioworks Holdings, Inc. (DNA), Tuesday announced that the company along with Carnegie Mellon University has been awarded a contract of upto $9.4 million to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders.
The project, named Biointegrated Implantable Systems for Cell-based Sensing and Therapy, focuses on implantable bioelectronic devices that utilize engineered cells to produce therapeutic molecules on demand and/or to measure disease biomarkers in realtime.
Under the contract, the company will utilize its capabilities in mammalian cell engineering and induced pluripotent stem cell engineering to create cells that produce and deliver therapeutic molecules and/or monitor the disease status.
Currently, Ginkgo's stock is trading at $9.28, down 1.59 percent on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ginkgo Bioworks, Carnegie Mellon University Secure $9.4 Mln To Build Devices For Disease Treatment

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $2.40. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 55%. A quarter ago, it was expected that this company would post a loss of $3.20 per share when it actually produced a loss of $3.20, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Ginkgo Bioworks, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $89.05 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 102.77%. This compares to year-ago revenues of $55.43 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Ginkgo Bioworks shares have lost about 87% since the beginning of the year versus the S&P 500's gain of 25.8%.
What's Next for Ginkgo Bioworks?
While Ginkgo Bioworks has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Ginkgo Bioworks: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$2.56 on $42.75 million in revenues for the coming quarter and -$12 on $180.84 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the broader Zacks Medical sector, Patterson Cos. (PDCO), is yet to report results for the quarter ended October 2024.
This medical supplies maker is expected to post quarterly earnings of $0.49 per share in its upcoming report, which represents a year-over-year change of -2%. The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level.
Patterson Cos.'s revenues are expected to be $1.64 billion, down 0.7% from the year-ago quarter.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
Ginkgo Bioworks Holdings, Inc. (DNA) : Free Stock Analysis Report
Patterson Companies, Inc. (PDCO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates

(RTTNews) - Ginkgo Bioworks Holdings, Inc. (DNA) revealed Loss for third quarter that decreased from last year
The company's earnings totaled -$56.40 million, or -$1.08 per share. This compares with -$302.89 million, or -$6.21 per share, in last year's third quarter.
The company's revenue for the quarter rose 60.7% to $89.05 million from $55.43 million last year.
Ginkgo Bioworks Holdings, Inc. earnings at a glance (GAAP) :
-Earnings (Q3): -$56.40 Mln. vs. -$302.89 Mln. last year. -EPS (Q3): -$1.08 vs. -$6.21 last year. -Revenue (Q3): $89.05 Mln vs. $55.43 Mln last year.
-Guidance: Full year revenue guidance: $215 - $235 Mln
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ginkgo Bioworks Holdings, Inc. Q3 Loss Declines

(RTTNews) - Ginkgo Bioworks Holdings, Inc. (DNA) will host a conference call at 5:30 PM ET on November 12, 2024, to discuss Q3 24 earnings results.
To access the live webcast, log on to https://investors.ginkgobioworks.com/events/default.aspx
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Indicator	TTM Median
P/E	0.00 20.61
Price/Sales	2.94 3.00
P/B	1.03 2.46
P/FCF	0.00 19.00

Indicator	TTM Median
ROE	0.00 19.40
ROA	0.00 7.15
ROI	0.00 9.64
Net Worth	0.59 0.24
Quick Ratio	0.00 1.72
Current Ratio	4.57 2.86

Indicator	TTM Median
Net Profit Margin	0.00 11.05
Operating Margin	0.00 14.16
Gross Margin	67.42 75.18
Return on tangible equity	0.00 40.61

Indicator	TTM Median
EPS	-0.86 0.46
EPS Forecast	-1.80 0.38
Revenue	19.00M 19.00M
Gross Profit	16.00M —
EBITDA	-158.00M —

Ginkgo Bioworks Holdings, Inc.

Recent quarterly and TTM performance

Valuation

Debts

Efficiency

Other ratios

Revenue